Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Other Operating Expenses (2016 - 2021)

Anika Therapeutics has reported Other Operating Expenses over the past 12 years, most recently at $825000.0 for Q4 2021.

  • Quarterly Other Operating Expenses rose 105.27% to $825000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $825000.0 through Sep 2022, up 108.47% year-over-year, with the annual reading at -$21.1 million for FY2021, 8.22% up from the prior year.
  • Other Operating Expenses was $825000.0 for Q4 2021 at Anika Therapeutics, up from -$3.4 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $8.7 million in Q4 2017 and troughed at -$24.3 million in Q4 2018.
  • The 5-year median for Other Operating Expenses is $5.0 million (2019), against an average of $1.0 million.
  • The largest YoY upside for Other Operating Expenses was 30763.64% in 2020 against a maximum downside of 10200.0% in 2020.
  • A 5-year view of Other Operating Expenses shows it stood at $8.7 million in 2017, then crashed by 378.56% to -$24.3 million in 2018, then surged by 99.37% to -$152000.0 in 2019, then crashed by 10200.0% to -$15.7 million in 2020, then skyrocketed by 105.27% to $825000.0 in 2021.
  • Per Business Quant, the three most recent readings for ANIK's Other Operating Expenses are $825000.0 (Q4 2021), -$3.4 million (Q3 2021), and $6.5 million (Q2 2021).